ArticleJournal of substance abuse treatment2018

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.

Jake R Morgan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.